{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:00:07Z","timestamp":1773284407313,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Henan Province Medical Science and Technology Joint Co-construction Project","award":["LHGJ20210967"],"award-info":[{"award-number":["LHGJ20210967"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03794-x","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:26:50Z","timestamp":1761208010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of ranibizumab combined with dexamethasone intravitreal implant versus ranibizumab monotherapy for macular edema secondary to retinal vein occlusion: a 12-month prospective, randomized study"],"prefix":"10.1007","volume":"45","author":[{"given":"Xiaohui","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-6375","authenticated-orcid":false,"given":"Yalong","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"4","key":"3794_CR1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/13816810.2019.1655772","volume":"40","author":"B Fern\u00e1ndez-Vega","year":"2019","unstructured":"Fern\u00e1ndez-Vega B, \u00c1lvarez L, Garc\u00eda M et al (2019) Association study of high-frequency variants of MTHFR gene with retinal vein occlusion in a Spanish population. Ophthalmic Genet 40(4):331\u2013337","journal-title":"Ophthalmic Genet"},{"issue":"1","key":"3794_CR2","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M et al (2019) Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health 9(1):010427","journal-title":"J Glob Health"},{"issue":"12","key":"3794_CR3","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/eye.2015.164","volume":"29","author":"S Sivaprasad","year":"2015","unstructured":"Sivaprasad S, Amoaku WM, Hykin P, RVO Guideline Group (2015) The royal college of ophthalmologists guidelines on retinal vein occlusions: executive summary. Eye (Lond) 29(12):1633\u20131638","journal-title":"Eye (Lond)"},{"key":"3794_CR4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/OPTH.S163859","volume":"12","author":"JM Jumper","year":"2018","unstructured":"Jumper JM, Dugel PU, Chen S et al (2018) Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin Ophthalmol 12:621\u2013629","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3794_CR5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313-319.e1","journal-title":"Ophthalmology"},{"issue":"3","key":"3794_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS et al (2019) Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica 242(3):123\u2013162","journal-title":"Ophthalmologica"},{"issue":"2","key":"3794_CR7","doi-asserted-by":"crossref","first-page":"P288","DOI":"10.1016\/j.ophtha.2019.09.029","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST et al (2020) Retinal vein occlusions preferred practice pattern\u00ae. Ophthalmology 127(2):P288\u2013P320","journal-title":"Ophthalmology"},{"issue":"10","key":"3794_CR8","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Awh CC, CRUISE Investigators et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041\u20132049","journal-title":"Ophthalmology"},{"key":"3794_CR9","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/OPTH.S140665","volume":"11","author":"A Pielen","year":"2017","unstructured":"Pielen A, Feltgen N, Isselmann B et al (2017) Efficacy and safety of aflibercept injections for macular edema secondary to central retinal vein occlusion: integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol 11:1533\u20131540","journal-title":"Clin Ophthalmol"},{"key":"3794_CR10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2147\/OPTH.S110793","volume":"10","author":"A Fujihara-Mino","year":"2016","unstructured":"Fujihara-Mino A, Mitamura Y, Inomoto N et al (2016) Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion. Clin Ophthalmol 10:1305\u20131313","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"3794_CR11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","volume":"16","author":"PA Campochiaro","year":"2008","unstructured":"Campochiaro PA, Hafiz G, Shah SM et al (2008) Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 16(4):791\u2013799","journal-title":"Mol Ther"},{"issue":"2","key":"3794_CR12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/2013.jamaophthalmol.228","volume":"131","author":"H Noma","year":"2013","unstructured":"Noma H, Mimura T, Eguchi S (2013) Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol 131(2):160\u2013165","journal-title":"JAMA Ophthalmol"},{"key":"3794_CR13","volume":"2013","author":"A Deobhakta","year":"2013","unstructured":"Deobhakta A, Chang LK (2013) Inflammation in retinal vein occlusion. Int J Inflam 2013:438412","journal-title":"Int J Inflam"},{"key":"3794_CR14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000320071","volume":"47","author":"AJ Augustin","year":"2010","unstructured":"Augustin AJ, Loewenstein A, Kuppermann BD (2010) Macular edema. General pathophysiology. Dev Ophthalmol 47:10\u201326","journal-title":"Dev Ophthalmol"},{"key":"3794_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich A, Matet A, Moulin A et al (2018) Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63:20\u201368","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"3794_CR16","first-page":"e119","volume":"95","author":"S Rezar-Dreindl","year":"2017","unstructured":"Rezar-Dreindl S, Eibenberger K, Pollreisz A et al (2017) Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol 95(1):e119\u2013e127","journal-title":"Acta Ophthalmol"},{"key":"3794_CR17","volume":"2020","author":"C Nicula","year":"2020","unstructured":"Nicula C, Nicula D, Rednik A et al (2020) Morphological and functional outcomes after intravitreal dexamethasone injection for macular edema in patients with central vein occlusion at 48-week follow-up. J Ophthalmol 2020:6830148","journal-title":"J Ophthalmol"},{"issue":"1","key":"3794_CR18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","volume":"256","author":"X Li","year":"2018","unstructured":"Li X, Zhou M, Xu G et al (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256(1):59\u201369","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"3794_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.18240\/ijo.2025.05.13","volume":"18","author":"G Karata\u015f","year":"2025","unstructured":"Karata\u015f G, \u00c7ak\u0131r A, Uzundede T, Aday \u00d6, \u00d6zo\u011fuz AM, Karata\u015f ME, Kabakc\u0131 AK (2025) Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. Int J Ophthalmol 18(5):876\u2013882. https:\/\/doi.org\/10.18240\/ijo.2025.05.13","journal-title":"Int J Ophthalmol"},{"key":"3794_CR20","doi-asserted-by":"crossref","unstructured":"Haller JA, Bandello F, Belfort R Jr, ,OZURDEX GENEVA Study Group, et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453\u20132460.","DOI":"10.1016\/j.ophtha.2011.05.014"},{"issue":"6","key":"3794_CR21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124\u20131133","journal-title":"Ophthalmology"},{"issue":"6","key":"3794_CR22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA et al (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1102\u20131112","journal-title":"Ophthalmology"},{"issue":"3","key":"3794_CR23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","volume":"98","author":"The Branch Vein Occlusion Study Group","year":"1984","unstructured":"The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271\u2013282","journal-title":"Am J Ophthalmol"},{"key":"3794_CR24","doi-asserted-by":"crossref","unstructured":"A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion (1995) The Central Vein Occlusion Study Group N report. Ophthalmology 102(10):1434\u20131444.","DOI":"10.1016\/S0161-6420(95)30848-2"},{"issue":"4","key":"3794_CR25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00417-019-04577-8","volume":"258","author":"C Giuffr\u00e8","year":"2020","unstructured":"Giuffr\u00e8 C, Cicinelli MV, Marchese A, Coppola M, Parodi MB, Bandello F (2020) Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 258(4):787\u2013793","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"3794_CR26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjophthalmol-2014-305661","volume":"99","author":"LP Iu","year":"2015","unstructured":"Iu LP, Zhao P, Yeung IY et al (2015) Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion. Br J Ophthalmol 99(2):210\u2013214","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"3794_CR27","first-page":"1289","volume":"32","author":"MA Singer","year":"2012","unstructured":"Singer MA, Bell DJ, Woods P et al (2012) Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 32(7):1289\u20131294","journal-title":"Retina"},{"key":"3794_CR28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OPTH.S119373","volume":"11","author":"MA Singer","year":"2017","unstructured":"Singer MA, Kingsley RM, Fiscella RG et al (2017) Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series. Clin Ophthalmol 11:31\u201338","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"3794_CR29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/eye.2017.230","volume":"32","author":"PL Lip","year":"2018","unstructured":"Lip PL, Muttuvelu DV, Tey A et al (2018) Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result. Eye (Lond) 32(3):537\u2013545","journal-title":"Eye (Lond)"},{"issue":"3","key":"3794_CR30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000442258","volume":"55","author":"C Chiquet","year":"2016","unstructured":"Chiquet C, Bron AM, Straub M et al (2016) Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Res 55(3):152\u2013158","journal-title":"Ophthalmic Res"},{"issue":"8","key":"3794_CR31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00417-018-4016-7","volume":"256","author":"J Blanc","year":"2018","unstructured":"Blanc J, Deschasse C, Kodjikian L et al (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol 256(8):1441\u20131448","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"3794_CR32","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00417-016-3394-y","volume":"254","author":"JF Korobelnik","year":"2016","unstructured":"Korobelnik JF, Kodjikian L, Delcourt C et al (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254(12):2307\u20132318","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3794_CR33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12886-022-02682-7","volume":"22","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu Z, Wang D et al (2022) Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. BMC Ophthalmol 22(1):472","journal-title":"BMC Ophthalmol"},{"key":"3794_CR34","first-page":"1057","volume":"8","author":"RK Maturi","year":"2014","unstructured":"Maturi RK, Chen V, Raghinaru D et al (2014) A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol 8:1057\u20131064","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3794_CR35","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100418","volume":"4","author":"D Nagasato","year":"2024","unstructured":"Nagasato D, Muraoka Y, Tanabe M et al (2024) Foveal thickness fluctuations in anti-VEGF treatment for central retinal vein occlusion. Ophthalmol Sci 4(2):100418","journal-title":"Ophthalmol Sci"},{"issue":"8","key":"3794_CR36","first-page":"1616","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Vazquez-Alfageme C, Sen P et al (2022) The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy. Eye (Lond) 36(8):1616\u20131621","journal-title":"Eye (Lond)"},{"issue":"2","key":"3794_CR37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/APO.0000000000000598","volume":"12","author":"F Romano","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH et al (2023) Update on retinal vein occlusion. Asia-Pac J Ophthalmol 12(2):196\u2013210","journal-title":"Asia-Pac J Ophthalmol"},{"key":"3794_CR38","volume":"2020","author":"W Song","year":"2020","unstructured":"Song W, Jiao W, Li F et al (2020) Evaluation of microvascular structure changes after Conbercept treatment on macular edema secondary to retinal vein occlusion. BioMed Res Int 2020:9046781","journal-title":"BioMed Res Int"},{"key":"3794_CR39","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100964","volume":"85","author":"SS Hayreh","year":"2021","unstructured":"Hayreh SS (2021) Photocoagulation for retinal vein occlusion. Prog Retin Eye Res 85:100964","journal-title":"Prog Retin Eye Res"},{"key":"3794_CR40","doi-asserted-by":"crossref","unstructured":"Brown DM, Campochiaro PA, Singh RP, CRUISE Investigators, et al. (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124\u20131133.e1.","DOI":"10.1016\/j.ophtha.2010.02.022"},{"issue":"6","key":"3794_CR41","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ophtha.2012.01.022","volume":"119","author":"DL Epstein","year":"2012","unstructured":"Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119(6):1184\u20131189","journal-title":"Ophthalmology"},{"issue":"8","key":"3794_CR42","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/02713683.2024.2343055","volume":"49","author":"X Cai","year":"2024","unstructured":"Cai X, Zhao J, Dang Y (2024) Combination therapy with anti-VEGF and intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion. Curr Eye Res 49(8):872\u2013878","journal-title":"Curr Eye Res"},{"issue":"2","key":"3794_CR43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tjo.2014.03.008","volume":"4","author":"M Nagpal","year":"2014","unstructured":"Nagpal M, Kheradiya N, Juneja S, Nagpal K (2014) Outcomes of combination therapy with dexamethasone implant and bevacizumab in macular edema related to vascular occlusions. Taiwan J Ophthalmol 4(2):74\u201378","journal-title":"Taiwan J Ophthalmol"},{"key":"3794_CR44","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/OPTH.S241044","volume":"14","author":"F Horner","year":"2020","unstructured":"Horner F, Davies J, Kirwan J et al (2020) Combination therapy for macular oedema in retinal vein occlusions: 3-year results from a real-world clinical practice. Clin Ophthalmol 14:955\u2013965","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"3794_CR45","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/jop.2017.0148","volume":"34","author":"G Garay-Aramburu","year":"2018","unstructured":"Garay-Aramburu G, G\u00f3mez-Moreno \u00c1 (2018) A 5-year follow-up study of the treatment of macular edema due to retinal vein occlusion using dexamethasone intravitreal implants. J Ocul Pharmacol Ther 34(6):436\u2013441","journal-title":"J Ocul Pharmacol Ther"},{"key":"3794_CR46","volume":"29","author":"F Ren","year":"2023","unstructured":"Ren F, Zhang Q, Yang M et al (2023) Evaluating the one-year efficacy of combined anti-VEGF and dexamethasone implant treatment for macular edema in retinal vein occlusions. Med Sci Monit 29:e939277","journal-title":"Med Sci Monit"},{"issue":"8","key":"3794_CR47","first-page":"763","volume":"38","author":"F Ehsan","year":"2023","unstructured":"Ehsan F, Khan MAB, Younus A et al (2023) Intravitreal injection of anti-vascular endothelial growth factors combined with corticosteroids for the treatment of macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. Semin Ophthalmol 38(8):763\u2013776","journal-title":"Semin Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03794-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03794-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03794-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:46Z","timestamp":1766170906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03794-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03794-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study adhered to the Declaration of Helsinki and was approved by the Ethics Committee of Sanmenxia Central Hospital (Approval No. 20210802). Written informed consent was obtained from the patient for publication of the details of their medical case and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants prior to enrollment. The study was registered with the Chinese Clinical Trial Registry (ChiCTR2400080048).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"436"}}